Advair and Symbicort: "Benefits Outweigh Risk" says an FDA Advisory Committee

Health Professional

Last week, the Food and Drug Administration (FDA) listened to presentations and comments from several members of an expert FDA advisory committee regarding the benefit-to-risk ratio of Long Acting Beta-agonist drugs (LABAs) -- namely Serevent (salmeterol), Foradil (formoterol), Advair (a combination of fluticasone and salmeterol) and Symbicort (a combination of budesonide and formoterol).

The FDA advisory panel voted, unanimously, that the benefit of Advair and Symbicort outweighed the risks of adverse effects in adults, but that the risks of Serevent and Foradil -- particularly when used without a anti-inflammatory steroid -- outweighed the benefits for asthmatics.

So, what does all of this mean for you?

Continue reading "Advair and Symbicort: "Benefits Outweight the Risk" Says an FDA Advisory Comittee.

Get more information on Advair, Symbicort and Long-Acting Beta Agonists here.